Abstract:Purpose Itraconazole (ITZ) is a synthetic triazole antifungal agent, which is widely used for treatment and prevention of fungal infections. The purpose of this study is to develop ITZ-loaded poly(lactic-co-glycolic acid) (PLGA) nanospheres (PLGA-ITZ-NS) as a new sustained-release formulation for intravenous ITZ administration. Materials and methods PLGA-ITZ-NS were prepared by a nanoprecipitation method and optimized by modifying the surfactant poloxamer 188 concentration and PLGA:ITZ ratio. Their physicochemical properties, including size, zeta potential, external morphology and encapsulation efficiency, were characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM) and high performance liquid chromatography (HPLC). The effect of the different selected lyoprotectants with various concentrations on NS particles size and surface charge were also assessed. Rapid and sensitive HPLC and liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods were developed to determine ITZ concentrations in formulation and in rat plasma, respectively. Pharmacokinetics of the optimum PLGA-ITZ-NS formulation was compared with the former commercial Sporanox® injection formulation using rats as the animal model. Noncompartmental pharmacokinetic parameters were obtained by WinNonlin® software. Results Optimal PLGA-ITZ-NS had a mean particle size of about 200 nm with a high homogeneity (polydispersity index ≈0.2), favorable zeta potential (approximately −20 to −30 mV) and encapsulation efficiency (72%). In addition, 2% w/v sucrose was selected as a lyoprotectant for NS freeze-drying. The newly developed LC-MS/MS assay was validated and found to be accurate and precise. The in vivo study showed that the NS formulation has a similar systemic bioavailability to Sporanox® while providing a sustained plasma level (> 100 ng/mL) for up to 24 hours after intravenous administration. Conclusion Our newly developed PLGA-ITZ-NS has shown great sustained release and comparable bioavailability with Sporanox®, therefore having the potential to be an alternative injectable formulation of ITZ.

Study on Preparation of Itraconazole Solid Lipid Nanoparticles

Orthogonal Experiments Optimizes the Formulations and Preparation Conditions of Itraconazole Solid Lipid Nanoparticles

Formulation and Evaluation of Lipid-based Nanoformulation of Itraconazole

Preparation of Actarit Solid Lipid Nanoparticles

Preparation and Physicochemical Properties of Solid Lipid Nanoparticles Containing Praziquantel

Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution.

Preparation of Itraconazole Amorphous Solid Dispersion and Preliminary Evaluation in Vitro

Preparation and Characterization of Itraconazole Albumin Nanosuspensions

The Increased Dissolution and Oral Absorption of Itraconazole by Nanocrystals with an Endogenous Small-Molecule Surfactant as a Stabilizer

Development of Liposome containing sodium deoxycholate to enhance oral bioavailability of itraconazole

Development and evaluation of novel itraconazole-loaded intravenous nanoparticles.

Preparation of Solid Lipid Nanoparticles by Emulsification-evaporation Technique

Preparation of Solid Lipid Nanoparticles Containing Praziquantel

Development of PLGA-based itraconazole injectable nanospheres for sustained release

Development of an itraconazole encapsulated polymeric nanoparticle platform for effective antifungal therapy

Preparation of Itraconazole Nanoparticles by Anti-Solvent Precipitation Method Using a Cascaded Microfluidic Device and an Ultrasonic Spray Drier

Albumin micro/nanoparticles entrapping liposomes for itraconazole green formulation

Preparation and physico-chemical properties of itraconazole polymeric micelles using mPEG-PLA as a drug carrier

Preparation of puerarin solid lipid nanoparticles for oral administration

Preparation and Characterization of Liranaftate Solid Lipid Nanoparticles

Preparation of Itraconazole Solid Dispersion with PVP and Dissolution Experiment in Vitro